CEPI is accelerating its programme to develop broadly protective coronavirus vaccines—a core part of US $ 3.5 billion pandemic preparedness plan
Nirsevimab is the first investigational long-acting antibody designed to protect all infants for the respiratory syncytial virus season with a single dose
Key takeaways of Q3FY22 quarter & conference call highlights
The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad
Immune responses were about two-to-three-fold higher in adolescents than in adults against all variants studied. Vaccine was well-tolerated with no safety signals identified
Key takeaways of recent quarter & conference call highlights
It has a total of 50 ANDA approvals from USFDA
The pharma division’s domestic business generated turnover of Rs. 219.85 crore for the last financial year
Pegfilgrastim is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving chemotherapy
Glenmark’s current portfolio consists of 173 products authorized for distribution in the U.S. marketplace and 46 ANDA’s pending approval with the U.S. FDA
Subscribe To Our Newsletter & Stay Updated
